This hematopoietic gene therapy offers a new treatment for children with severe leukocyte adhesion deficiency-I without matched transplant donors.

Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33, an alarmin cytokine.

HealthDay News — For individuals with attention-deficit/hyperactivity disorder (ADHD), sustained treatment with methylphenidate is not associated with the risk for nonaffective psychosis, according to ...

The agency said $5B is needed annually for TB research, but funding cuts have made it difficult to reach that goal ...

Patients reported feeling comfortable interacting with care team remotely and felt emotionally supported by care team ...

The increased risk for dementia seen in association with infectious diseases is not attributable to comorbid dementia-related ...

Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

Lifyorli combo approved for ovarian cancer; mixed results from Lyme disease vaccine trial; treatment approved for rare Hunter ...

The US Food and Drug Administration (FDA) has warned a biotech company about claims that its bladder cancer drug could treat and prevent multiple types of cance ...

The melanocortin 4 receptor agonist setmelanotide is now FDA approved for weight management in adults and children with ...

HealthDay News — Glucagon-like peptide-1 (GLP-1) receptor agonists, especially semaglutide, are associated with a reduced risk for worsening of anxiety and depression that co-occur with diabetes and ...